Literature DB >> 16319920

Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics.

Christine E Marx1, Robert D Stevens, Lawrence J Shampine, Veska Uzunova, William T Trost, Marian I Butterfield, Mark W Massing, Robert M Hamer, A Leslie Morrow, Jeffrey A Lieberman.   

Abstract

Evidence suggests that neuroactive steroids may be candidate modulators of schizophrenia pathophysiology and therapeutics. We therefore investigated neuroactive steroid levels in post-mortem brain tissue from subjects with schizophrenia, bipolar disorder, nonpsychotic depression, and control subjects to determine if neuroactive steroids are altered in these disorders. Posterior cingulate and parietal cortex tissue from the Stanley Foundation Neuropathology Consortium collection was analyzed for neuroactive steroids by negative ion chemical ionization gas chromatography/mass spectrometry preceded by high-performance liquid chromatography. Subjects with schizophrenia, bipolar disorder, nonpsychotic depression, and control subjects were group matched for age, sex, ethnicity, brain pH, and post-mortem interval (n = 14-15 per group, 59-60 subjects total). Statistical analyses were performed by ANOVA with post-hoc Dunnett tests on log transformed neuroactive steroid levels. Pregnenolone and allopregnanolone were present in human post-mortem brain tissue at considerably higher concentrations than typically observed in serum or plasma. Pregnenolone and dehydroepiandrosterone levels were higher in subjects with schizophrenia and bipolar disorder compared to control subjects in both posterior cingulate and parietal cortex. Allopregnanolone levels tended to be decreased in parietal cortex in subjects with schizophrenia compared to control subjects. Neuroactive steroids are present in human post-mortem brain tissue at physiologically relevant concentrations and altered in subjects with schizophrenia and bipolar disorder. A number of neuroactive steroids act at inhibitory GABA(A) and excitatory NMDA receptors and demonstrate neuroprotective and neurotrophic effects. Neuroactive steroids may therefore be candidate modulators of the pathophysiology of schizophrenia and bipolar disorder, and relevant to the treatment of these disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16319920     DOI: 10.1038/sj.npp.1300952

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  53 in total

Review 1.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

Review 2.  GABA(A) receptors and their associated proteins: implications in the etiology and treatment of schizophrenia and related disorders.

Authors:  Erik I Charych; Feng Liu; Stephen J Moss; Nicholas J Brandon
Journal:  Neuropharmacology       Date:  2009-07-23       Impact factor: 5.250

3.  Overexpression of the steroidogenic enzyme cytochrome P450 side chain cleavage in the ventral tegmental area increases 3α,5α-THP and reduces long-term operant ethanol self-administration.

Authors:  Jason B Cook; David F Werner; Antoniette M Maldonado-Devincci; Maggie N Leonard; Kristen R Fisher; Todd K O'Buckley; Patrizia Porcu; Thomas J McCown; Joyce Besheer; Clyde W Hodge; A Leslie Morrow
Journal:  J Neurosci       Date:  2014-04-23       Impact factor: 6.167

4.  Differential effects of ethanol on serum GABAergic 3alpha,5alpha/3alpha,5beta neuroactive steroids in mice, rats, cynomolgus monkeys, and humans.

Authors:  Patrizia Porcu; Todd K O'Buckley; Sarah E Alward; Soomin C Song; Kathleen A Grant; Harriet de Wit; A Leslie Morrow
Journal:  Alcohol Clin Exp Res       Date:  2009-12-17       Impact factor: 3.455

5.  Ethanol alters local cellular levels of (3α,5α)-3-hydroxypregnan-20-one (3α,5α-THP) independent of the adrenals in subcortical brain regions.

Authors:  Jason B Cook; Stephanie M Nelli; Mackenzie R Neighbors; Danielle H Morrow; Todd K O'Buckley; Antoniette M Maldonado-Devincci; A Leslie Morrow
Journal:  Neuropsychopharmacology       Date:  2014-02-25       Impact factor: 7.853

6.  Targeting neurosteroid synthesis as a therapy for schizophrenia-related alterations induced by early psychosocial stress.

Authors:  Roberto Frau; Federico Abbiati; Valentina Bini; Alberto Casti; Donatella Caruso; Paola Devoto; Marco Bortolato
Journal:  Schizophr Res       Date:  2015-05-18       Impact factor: 4.939

7.  A study of subunit selectivity, mechanism and site of action of the delta selective compound 2 (DS2) at human recombinant and rodent native GABA(A) receptors.

Authors:  M L Jensen; K A Wafford; A R Brown; D Belelli; J J Lambert; N R Mirza
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

8.  Allopregnanolone levels are reduced in temporal cortex in patients with Alzheimer's disease compared to cognitively intact control subjects.

Authors:  Jennifer C Naylor; Jason D Kilts; Christine M Hulette; David C Steffens; Dan G Blazer; John F Ervin; Jennifer L Strauss; Trina B Allen; Mark W Massing; Victoria M Payne; Nagy A Youssef; Lawrence J Shampine; Christine E Marx
Journal:  Biochim Biophys Acta       Date:  2010-05-19

9.  Simultaneous quantification of GABAergic 3alpha,5alpha/3alpha,5beta neuroactive steroids in human and rat serum.

Authors:  Patrizia Porcu; Todd K O'Buckley; Sarah E Alward; Christine E Marx; Lawrence J Shampine; Susan S Girdler; A Leslie Morrow
Journal:  Steroids       Date:  2009-01-13       Impact factor: 2.668

10.  Effects of the neuroactive steroid allopregnanolone on intracranial self-stimulation in C57BL/6J mice.

Authors:  A Leslie Morrow; C J Malanga; Eric W Fish; Buddy J Whitman; Jeff F DiBerto; J Elliott Robinson
Journal:  Psychopharmacology (Berl)       Date:  2014-05-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.